Antibiotic-resistant bacteria are a significant public health concern and motivate efforts to develop new classes of antibiotics. One such class of antibiotics is the arylomycins, which target type I signal peptidase (SPase), the enzyme responsible for the release of secreted proteins from their N-terminal leader sequences. Despite the essentiality, conservation, and relative accessibility of SPase, the activity of the arylomycins is limited against some bacteria, including the important human pathogen Staphylococcus aureus. To understand the origins of the limited activity against S. aureus, we characterized the susceptibility of a panel of strains to two arylomycin derivatives, arylomycin A-C 16 and its more potent analog arylomycin M131. We observed a wide range of susceptibilities to the two arylomycins and found that resistant strains were sensitized by cotreatment with tunicamycin, which inhibits the first step of wall teichoic acid synthesis. To further understand how S. aureus responds to the arylomycins, we profiled the transcriptional response of S. aureus NCTC 8325 to growth-inhibitory concentrations of arylomycin M131 and found that it upregulates the cell wall stress stimulon (CWSS) and an operon consisting of a putative transcriptional regulator and three hypothetical proteins. Interestingly, we found that mutations in the putative transcriptional regulator are correlated with resistance, and selection for resistance ex vivo demonstrated that mutations in this gene are sufficient for resistance. The results begin to elucidate how S. aureus copes with secretion stress and how it evolves resistance to the inhibition of SPase.
T he widespread use of antibiotics imposes a relentless selection pressure on bacteria that has driven the evolution of multidrug resistance in many pathogens, and novel classes of antibiotics are needed (1, 2) . Staphylococcus aureus has emerged as a particular health concern due to its ability to cause a wide range of infections, ranging from superficial lesions such as skin abscesses and wound infections to more systemic and life-threatening conditions such as osteomyelitis, endocarditis, pneumonia, septicemia, and toxinoses. To infect different tissues, S. aureus relies on the secretion of virulence factors that facilitate adhesion and colonization, promote dissemination, facilitate the evasion of the host immune response, and scavenge nutrients and minerals from the environment (3) (4) (5) (6) . The majority of proteins destined for export out of the cytoplasm are synthesized as preproteins with N-terminal signal peptide sequences, which target them to the general secretory (Sec) pathway (7) (8) (9) , and these leader peptides ultimately must be removed by the proteolytic activity of type I signal peptidase (SPase) (10) .
SPase has long been appreciated as a promising target for antibiotic therapy, and a search for inhibitors led to the identification in 2002 of the arylomycin family of natural product lipopeptide antibiotics from a strain of Streptomyces ( Fig. 1) (11) (12) (13) . Despite the essentiality, conservation, and relative accessibility of SPase (10, 14) , the arylomycins were initially reported to have a narrow spectrum of activity (12, 13) . However, it has since been shown that in many cases the limited activity of the arylomycins results not from any intrinsic limitations of the antibiotic or its target but rather from the sporadic presence of a specific SPase mutation that installs a proline in the binding pocket and reduces the affinity with which the arylomycin binds (15) . By designing derivatives that overcome the loss in affinity, we (16) (17) (18) (19) and others (20) have been able to broaden the spectrum of the arylomycin scaffold to include several additional pathogens. Of particular note is the derivative arylomycin M131, disclosed by Merck, which has promising activity against S. aureus (20) . Nonetheless, we have demonstrated in both Gram-positive and Gram-negative bacteria that high-level resistance to the arylomycin scaffold may result from mechanisms other than the "resistance"-conferring Pro residue in SPase (21) , and these additional mechanisms currently limit efforts to develop the arylomycins as therapeutic agents. In this study, we characterize the activity of two arylomycin derivatives, arylomycin A-C 16 and arylomycin M131 (Fig. 1) , against a panel of S. aureus strains. We observed a range of susceptibilities, and further characterization revealed that resistance is mediated by the mutation of a putative transcriptional regulator. The results have important implications for our understanding of SPase and protein secretion and the potential of the arylomycins as broad-spectrum antibiotics.
MATERIALS AND METHODS
Bacterial strains, growth conditions, and antibiotics. S. aureus strains were routinely cultured using tryptic soy broth (TSB) or tryptic soy agar (TSA) at 37°C. Cation-adjusted Mueller-Hinton broth was used for the MIC assays. Stock solutions of antibiotics were made in dimethyl sulfoxide (DMSO), with the exception of chloramphenicol, which was made in ethanol. Antibiotics used for selection during cloning were chloramphenicol at 20 g/ml and ampicillin at 100 g/ml. Arylomycin A-C 16 and arylomycin M131 were synthesized as previously described (20, 22) . Strains used are listed in Table S1 in the supplemental material. Clinical isolates (no identifiers) were obtained from the University of California, San Diego (UCSD) Microbiology Laboratory (methicillin-susceptible S. aureus [MSSA] panel) and from the Nizet Lab at UCSD (methicillinresistant S. aureus [MRSA] panel). Optical density readings (optical density at 600 nm [OD 600 ])for large-volume cultures were taken using a BioPhotometer (Eppendorf), and optical density readings (OD 590 ) of cultures in 96-well plates were taken using an EnVision 2103 multilabel reader (PerkinElmer).
Microscopy. Cell morphology was assessed using light microscopy. S. aureus was grown on TSA overnight, spread on glass slides, and heat fixed. Slides were then subjected to Gram staining. Slides were viewed using a Nikon E600W microscope with a 100ϫ oil immersion lens, and images were collected using IPLab v3.9 (Scanalytics, Inc., Rockville, MD).
RNA preparation. For total RNA extraction, cells were grown to an OD 600 of 2.0 (unless stated otherwise) and treated with 4ϫ MIC of arylomycin M131 (16 g/ml) or the DMSO control for 0, 30, and 120 min before 10 ml of cells were pelleted by centrifugation. Cell pellets were resuspended in 2 ml of RNAprotect bacterial reagent (Qiagen) to stabilize the RNA. RNAprotect was removed by centrifugation. To aid in lysis, cells were resuspended in RNase-free water (200 l) containing 50 g of lysostaphin (Sigma) and 90 g of lysozyme (Sigma) and incubated at 37°C for 60 min with shaking. Cells were lysed by the addition of 100-m glass beads followed by vortexing for 1 min. TRIzol (2 ml; Invitrogen) was added, the cell suspension was vortexed again for 1 min, and then the lysate was processed to isolate RNA according to the manufacturer's guidelines for using TRIzol. Following TRIzol extraction, the RNA was subjected to DNase I treatment and cleanup using an RNeasy minikit (Qiagen).
RNA-Seq analysis. Analysis was performed using the DNA microarray core facility at The Scripps Research Institute. The library was created using the Epicentre ScriptSeq complete kit for bacteria (Gram positive) with 400 ng of DNA-free RNA used for each sample, following the manufacturer's instructions. All samples were sequenced on an Illumina HiSeq2000 system located at the Scripps DNA sequencing facility. Reads were trimmed to 100 nucleotides (nt). mRNA-Seq TopHat v1.4.1 with Bowtie 2 was used to align the genome using the genome reference (S. aureus subsp_NCTC 8325). For the mRNA annotation, Partek software v6.6 was used. Each time point consisted of two independent biological replicates. The number of aligned reads for most samples was ϳ75% or ϳ8 million reads. Transcripts identified with fewer than 40 reads were discarded to eliminate noise. The resulting filtered data set was then used with the edgeR program and the traditional general linear modeling (GLM) approach to find the transcripts that were significantly changed between the arylomycin M131 time points and the DMSO baseline.
Antibiotic susceptibility testing. Susceptibility to antibiotics was determined using the Clinical and Laboratory Standards Institute broth microdilution method (23) . Briefly, antibiotics were prepared as 2-fold dilutions in 96-well plates containing cation-adjusted Mueller-Hinton broth. Wells were inoculated from a fresh plate scrape to a final concentration of 5 ϫ 10 5 CFU/ml and incubated at 37°C for 20 h. Growth was observed visually. Antibiotics were used at their respective 0.5ϫ MICs when added in combination with arylomycin M131 or arylomycin A-C 16 , with the exception of tunicamycin, which was added at a subinhibitory concentration of 2 g/ml. All MICs reported are the average of at least three independent determinations.
RT-PCR. RNA (2 g) was converted to cDNA with the SuperScript III first-strand synthesis system (Invitrogen) using the manufacturer's protocol. SYBR Select (Invitrogen) and a Bio-Rad CFX Connect real-time system were used for reverse transcription (RT)-PCR analysis using the primers (625 nM) listed in Table S2 in the supplemental material and a cDNA template (50 ng). The 16S RNA gene was used to normalize gene expression between samples. Gene expression changes were measured in triplicate by the ⌬⌬C T method using CFX Manager 3.0 software (Bio-Rad).
Protein synthesis. Overnight cultures were diluted in fresh TSB to an OD 600 of 0.05 and grown to an OD 600 of 0.6 at 37°C, at which point 35 S-labeled methionine (PerkinElmer) was added to a final concentration of 100 Ci/ml, and 200-l samples were taken 5, 10, 15, and 20 min postaddition. Trichloroacetic acid (TCA) (10%, 1 ml) and bovine serum albumin (BSA) (1 mg/ml, 100 l) were added to each sample. Samples were vacuum filtered using 96-well filter plates (1.0-m glass fiber type B; MultiScreen) and washed with 10% TCA (2 ml) and 95% ethanol (2 ml Ex vivo evolution of arylomycin M131 resistance. S. aureus N315 (2.2 ϫ 10 9 CFU) was plated on Mueller-Hinton agar (100-mm plate) in the presence of 16ϫ MIC of arylomycin M131 (16 g/ml) and grown overnight at 37°C. Selected isolates were restreaked twice in the presence of 16 g/ml arylomycin M131, followed by twice without selection on Mueller-Hinton agar, and the MIC was verified after every restreak. The spsIB, vraR, and SA0337 (SAOUHSC_00331) genes were amplified using Phusion HF DNA polymerase (New England BioLabs) and the primers listed in Table S2 in the supplemental material, and PCR products were sequenced. MICs to a panel of antibiotics were also determined for each isolate. The evolved mutant AC0001 was complemented by cloning the wild-type N315 SA0337 (Leu22) and native promoter into the pRB473 vector using the EcoRI and BamHI sites and primers SA0037_F/R listed in Table S2 . The SA0337⌬TVF allele evolved in AC0002 was cloned with the same primers used for the wild-type SA0337 gene. Complementation plasmids, including empty vector, were built using XL10-Gold and transformed into the dcm mutant Escherichia coli strain DC10B for electroporation into S. aureus (24) . Electrocompetent N315 and AC0001 were made by diluting overnight cultures grown in TSB 1:100 into fresh TSB and grown to an OD 600 of 0.3 to 0.4. Cells were pelleted by centrifugation at 1,500 relative centrifugal force (RCF) for 20 min and washed in 1 volume of 10% sterile glycerol followed by washes of 0.5ϫ and 0.1ϫ the volume in 10% glycerol and resuspended in 0.3ϫ the original volume. For electroporation, DNA (1 g) was added to the electrocompetent cell suspension (50 l) in a 2-mm gap electroporation cuvette and pulsed in a Bio-Rad capacitance extender III (2.0 kV, 200 ⍀, 25 F). Cells were recovered by the addition of 1 ml of TSA containing 250 mM sucrose and grown for 3 h at 37°C before plating on TSB with chloramphenicol for plasmid selection. MICs to arylomycin M131 were analyzed in the presence of 20 g/ml chloramphenicol to select for the plasmid. Reported MICs are the average of at least three independent determinations.
RESULTS
Staphylococcus aureus is heterogeneously susceptible to the arylomycins. As an initial screen, we first determined the MIC of arylomycin A-C 16 with a panel of S. aureus strains containing 13 well-characterized research strains (including COL, N315, USA300, and NCTC 8325) (see Table S1 in the supplemental material for the full list) and 104 clinical isolates (Fig. 1) . The majority of strains had MICs of 16 to 32 g/ml (85 strains) or Ͼ128 g/ml (16 strains, including USA300 and NCTC 8325). The SPase gene (spsIB) of each strain was sequenced and in all cases found to encode the resistance-conferring Pro29 (for comparison, the arylomycin-sensitizing mutation P29S confers the NCTC 8325 strain with an MIC of 2 g/ml [15] ). The sequences were 98 to 100% identical, and, importantly, no correlation was observed between sequence and susceptibility. We next determined the MIC of arylomycin M131 with the 16 arylomycin A-C 16 -resistant strains, as well as 16 additional strains selected randomly from the group with MICs between 16 and 32 g/ml (including COL and N315). Two of the arylomycin A-C 16 -resistant strains were also resistant to arylomycin M131 (MIC of Ͼ32 g/ml), while the remainder, including USA300 and NCTC 8325 were sensitive (MIC of 1 to 4 g/ml) (Fig. 1) .
Phenotypic analysis of arylomycin-sensitive and -resistant strains. We next examined a variety of phenotypes to identify whether any are correlated with susceptibility to the arylomycins. The sensitive and resistant strains showed no consistent differences in growth or cell morphology (see Fig. S1 in the supplemental material). When strains were subjected to different antibiotics, including penicillin G, oxacillin, vancomycin, daptomycin, trimethoprim, gentamicin, ciprofloxacin, carbonyl cyanide 3-chlorophenyl hydrazone (CCCP), tetracycline, rifampin, or erythromycin, none of the sensitivities were found to correlate with arylomycin susceptibility (see Table S3 in the supplemental material).
The inhibition of SPase is likely to result in the accumulation of proteins anchored to the cytoplasmic membrane, and the optimal folding and/or tolerance of such proteins in Bacillus subtilis has been shown to be dependent on the modification of teichoic acids (25) , which are anionic polymers that are a significant component of the S. aureus cell envelope. Thus, to further explore possible phenotypes associated with arylomycin resistance, we examined the effect of coadministration of subinhibitory concentrations of tunicamycin, which at the concentrations employed is thought to be a selective inhibitor of TarO (also referred to as TagO), the enzyme responsible for catalyzing the first step of wall teichoic acid (WTA) biosynthesis (26) ( Table 1) . Coadministration of tunicamycin had a relatively small effect on the arylomycin sensitivity of susceptible strains. However, strains resistant to arylomycin A-C 16 (but susceptible to arylomycin M131) were sensitized to arylomycin A-C 16 by tunicamycin. Similarly, strains resistant to arylomycin M131 (and also to arylomycin A-C 16 ) were sensitized to arylomycin M131 by tunicamycin but not to arylomycin A-C 16 (although these strains did show significantly reduced growth in the presence of arylomycin A-C 16 ). To confirm that these changes in sensitivity result from the inhibition of TarO, we examined the arylomycin susceptibilities of two arylomycin A-C 16 -sensitive and two arylomycin A-C 16 -resistant tarO deletion strains (26-28) (Table 2). Virtually identical results were observed, confirming that the changes in sensitivity result from the inhibition of TarO. In addition, tunicamycin and the arylomycins were no longer synergistic in the tarO deletion strains.
Transcriptional response to SPase inhibition. To characterize the response of S. aureus to the arylomycins, we transcriptionally profiled S. aureus NCTC 8325 grown in the absence and presence of arylomycin M131 (4ϫ MIC). After 30 and 120 min of growth, RNA was recovered and subjected to RNA-Seq in order to characterize the response before and after the observable inhibition of growth (Fig. 2) . We found that the addition of arylomycin M131 resulted in a strong transcriptional response: ϳ400 genes exhibited a Ͼ1.8-fold difference in abundance with arylomycin treatment relative to that for the mock-treated control, with approximately equal numbers of genes upregulated and downregulated (see Tables S4 and S5 in the supplemental material).
Strong induction of the cell wall stress stimulon (CWSS) was observed, including the induction of the two-component response regulator VraRS (increased 3-fold), as well as 23 of the ϳ50 genes thought to be at least partially under its control (increased 2-to 5-fold) (see Table S4 in the supplemental material). Strong upregulation was observed for vraX, which encodes a small protein of unknown function and which is induced by antibiotics that disrupt the cell wall, reaching an 11-fold increase over the DMSO control 30 min after arylomycin treatment. In addition to HtrA and PrsA, which are part of the CWSS, several additional genes thought to be involved in protein fate also showed increased transcription, including the chaperone GroES and multiple methionine sulfoxide reductases. We also observed increased transcription of five proteins involved in ribosome modification (ϳ2-to 3-fold). Very few genes known to be involved in metabolism were induced, with the exception of the two subunits of glutamate synthase (gltB and gltD), which were ϳ7-fold increased after 2 h. Genes involved in iron acquisition were upregulated (2-to 3-fold at 120 min), as were the genes responsible for riboflavin transport and synthesis. Finally, in addition to several genes encoding proteins of unknown function, an apparent operon, SAOUHSC_00331-334, which encodes a putative transcriptional regulator and three hypothetical membrane proteins, was also upregulated (2-to 10-fold).
While the transcription of a variety of genes was found to be downregulated by addition of the arylomycin, the majority were only downregulated 2-to 3-fold, with the greater downregulation observed only at the 120-min time point. A large proportion of these genes are involved in cellular metabolism, particularly with cellular respiration, including glycolysis, the citric acid cycle, the electron transport chain, and the phosphotransferase system. Genes encoding components of the general secretory pathway were downregulated at 120 min, including the essential components SecA and SecY, as well as the accessory proteins Asp1, Asp2, Asp3, and SecY2. The transcription of a variety of genes encoding proteins with predicted N-terminal leader sequences, suggesting that they are SPase substrates, was also downregulated (23 genes, with 2-to 6-fold decreased transcription), as was that of 18 genes of the pyr and pur operons, involved in nucleotide synthesis (2-fold at both 30 and 120 min). Reduced transcription (2-fold at 120 min) was also observed with 48 genes encoding proteins involved in ribosome assembly or translation. Finally, we observed reduced transcription of lrgAB (2-to 3-fold), which encodes a holin/antiholin-like system believed to be involved in the maintenance of the proton motive force (29, 30) .
Although the CWSS is induced by arylomycin M131, it does not contribute to arylomycin resistance. The strong induction of the CWSS by arylomycin M131 motivated us to examine its role in arylomycin resistance. In addition, induction of the CWSS is known to play a role in the response to other antibiotics that compromise the integrity of the cell envelope, such as daptomy- 
FIG 2 Growth inhibition of S. aureus NCTC 8325 by arylomycin M131. S.
aureus was grown with shaking in TSB for 4 h at 37°C to an OD 600 of 2. The culture was split and treated with 4ϫ MIC of arylomycin M131 or DMSO, and growth was monitored for an additional 6 h. Samples were taken for global transcriptional analysis 30 and 120 min after arylomycin M131 addition, corresponding to 4.5 and 6 h of total growth, respectively.
cin, ␤-lactams, and vancomycin (31-33). Thus, we examined the induction of vraR and two genes under its control, spsIB and prsA, by arylomycin M131 in representative sensitive and resistant members of the panel of S. aureus strains (Fig. 3) . Consistent with the transcriptional profiling data, we observed induction of each gene in the sensitive strains (although less so with spsIB). While we also observed induction in the strains that are resistant to arylomycin A-C 16 (but susceptible to arylomycin M131), no induction was observed in the strains that are resistant arylomycin M131, suggesting that resistance abrogates the inducing signal. We also compared the arylomycin M131 sensitivity of several vraR and/or vraS deletion strains (32, 34, 35) and their respective parental strains and found only small (ϳ2-fold) differences (Table 3) . Thus, we conclude that while the CWSS is induced by arylomycin M131 and might contribute to the cell's response, it does not contribute to high-level resistance. Contribution of protein translation to arylomycin resistance. The transcriptional response to arylomycin M131 included changes in many proteins involved in protein translation. Moreover, it has been demonstrated previously that it is possible to compensate for loss-of-function mutations in components of the general secretory pathway in E. coli by inhibiting protein synthesis, likely because it reduces the amount of proteins that need to be secreted or that form toxic structures during aberrant secretion (36) (37) (38) (39) . Thus, to explore the possible contribution of protein synthesis to arylomycin resistance, we examined sensitivity in the presence of subinhibitory concentrations of the translation inhibitor tetracycline. Surprisingly, the addition of subinhibitory concentrations of tetracycline (0.5ϫ MIC) resulted in the sensitization of resistant strains ( Table 4 ). The addition of the transcription inhibitor rifampin had a similar effect. Overall, the data suggest that transcription and translation are required for arylomycin resistance. However, no significant differences were observed in the levels of total protein synthesis in sensitive and resistant strains in the absence of arylomycin, as measured via 35 S metabolic labeling (see Fig. S2 in the supplemental material), suggesting that resistance is mediated by the synthesis of a few specific proteins, the changes of which are difficult to detect in the presence of all of the other proteins synthesized.
Mutations in the putative Cro-like repressor SAOUHSC_ 00331 are correlated with arylomycin resistance. One of most significant changes in transcript levels with the addition of arylomycin M131 was the induction of an apparent operon consisting of four genes, including a putative transcriptional regulator (SAOUHSC_00331) and three putative membrane proteins (SAOUHSC_00332-334). To explore the potential contribution of this operon to resistance, we first sequenced the SAOUHSC_ 00331 gene in a representative subset of the S. aureus panel that included 11 sensitive and 11 resistant strains (Fig. 4) . Interestingly, two alleles of SAOUHSC_00331 were observed, one encoding Leu as the amino acid at residue 22 and one encoding Gln at the same position. Ten of the 11 sensitive strains examined encoded Leu22. The single exception of a sensitive strain encoding Leu22 was MRSA COL, which nonetheless grew poorly even in the absence of an arylomycin. In contrast, all 11 of the arylomycin A-C 16 -resistant strains, including 2 that are resistant to arylomycin M131, encoded Gln at residue 22. Thus, arylomycin susceptibility appears correlated with differences in the putative transcriptional regulator SAOUHSC_00331 or a genetically linked factor.
Ex vivo evolution of arylomycin resistance and confirmation that mutations in SAOUHSC_00331 underlie arylomycin resistance. To investigate the minimal changes required for arylomycin resistance, we performed a selection experiment to isolate mutants of the arylomycin-sensitive S. aureus N315 that are able to grow in the presence of 16 g/ml arylomycin M131 (corresponding to 16ϫ MIC). Mutants arose at a frequency of 2 ϫ 10 Ϫ8 and
FIG 3
Induction of the CWSS in arylomycin-sensitive and -resistant strains by arylomycin M131. S. aureus strains were grown in TSB to an OD 600 of 1.0 and subjected to either DMSO or 4 g/ml arylomycin M131 for 30 min. Extracted RNA was converted to cDNA and subjected to RT-PCR using primers to amplify genes involved in the CWSS (vraR, spsIB, and prsA). gmk was used as an external control, and gene expression was normalized to 16S rRNA. Fold changes in gene expression were calculated using the ⌬⌬C T method; data shown are the average and standard error of the mean (SEM) for three independent samples. were found to have Ͼ32-fold higher resistance to arylomycin M131 than the parental N315 strain. Four resistant isolates were selected for further analysis. Like the arylomycin-resistant clinical isolates, none of the selected mutants showed altered sensitivity to a panel of antibiotics (oxacillin, vancomycin, daptomycin, trimethoprim, gentamicin, ciprofloxacin, tetracycline, rifampin, and erythromycin). However, none of the four ex vivo evolved mutants showed synergy between arylomycin A-C 16 and tunicamycin. This suggests that resistances evolved in the clinic and in the laboratory are not identical. The sequences of spsIB and vraR were analyzed in each of the four evolved isolates and found to be identical to that of the parental strain N315. However, three of the four resistant mutants contained a single mutation in SAOUHSC_00331 (SA0337 in N315 genome) relative to S. aureus N315 (Fig. 4) . One resistant mutant contained a CGA to TGA (stop) mutation at codon four (AC0001), while two isolates (AC0002 and AC0003) encoded proteins with the same three-codon deletion near the C terminus, which by analogy to the Cro repressor, is within the dimerization domain required for function (40) . To confirm that mutation of SAOUHSC_00331 is sufficient to confer resistance, we cloned the wild-type gene from S. aureus N315 (encoding Leu22) into pRB473 under the control of its native promoter and transformed the resulting vector into strain AC0001. The wild-type gene was found to restore sensitivity to arylomycin M131 (MIC of 4 g/ml) ( Table 5) . As a control, the arylomycin-resistant allele from strain AC0002, cloned and expressed in the same manner, did not restore sensitivity.
DISCUSSION
Although secretion is an essential process in S. aureus, little is known about how S. aureus responds to secretion stress in general and the inhibition of SPase in particular. Thus, understanding the activity of the arylomycins against S. aureus, the bacterial response, and the evolution of resistance is expected to elucidate fundamentally important aspects of S. aureus, in addition to helping to evaluate and potentially optimize the arylomycins as therapeutic agents. The analysis of the activity of arylomycin A-C 16 and arylomycin M131 against our panel of laboratory strains and clinical isolates revealed MIC 50 and MIC 90 values of 16 and Ͼ128 g/ml and 2 and 4 g/ml, respectively. With both arylomycins, the strains predominantly grouped into two sets, those with MICs between 16 and 32 g/ml or Ͼ128 g/ml for arylomycin A-C 16 and those with MICs of 1 to 4 g/ml or Ͼ32 g/ml for arylomycin M131. Interestingly, susceptibility was not correlated with the SPase sequence, indicating the existence of other factors capable of mediating high-level resistance. To begin to understand the response of S. aureus to the arylomycins, we transcriptionally profiled strain NCTC 8325 after 30 or 120 min of growth in the absence and presence of arylomycin M131 (4ϫ MIC). A large proportion of the downregulated genes are involved in cellular metabolism, DNA synthesis, protein translation, and protein secretion, and the decreases were only significant after 120 min of arylomycin treatment, suggesting that they may be caused by a reduction in the growth rate and not the inhibition of SPase per se. For example, 48 genes encoding proteins involved in ribosome assembly and translation were downregulated 2-fold at 120 min, and mechanisms coupling the transcription of these genes to the growth rate are well known (41) . Nonetheless, given the apparent contribution of protein synthesis to arylomycin resistance, it is interesting to note that the addition of arylomycin M131 increased transcription of five genes whose protein products are predicted to affect translation. RimL and RimI are acetyltransferases that acetylate the ribosome proteins L12 and S18, respectively (42) (43) (44) . Based on sequence homology, SAOUHSC_02113 (homolog of E. coli RimC [45] ) and SAOUHSC_02769 (Kgm family [46] ) appear to be S-adenosylmethionine-dependent ribosomal methyltransferases. The sequence analysis of SAOUHSC_01443 (by BLASTp [47] ) suggests that it is a homolog of RNase H, which is an endonuclease that degrades the RNA of RNA-DNA hybrid duplexes (48) .
One of the strongest responses generated by arylomycin M131 is the induction of the CWSS. The CWSS controls processes that aid in protein folding and secretion (e.g., spsIB, htrA, mrsA, and prsA) and alterations to the cell wall (e.g., fmt, murAB, and tcaA) (32, 49, 50) . While the CWSS is known to respond to cell walldamaging agents, such as oxacillin, daptomycin, and vancomycin, it has not previously been implicated as part of a response to cell membrane damage or to secretion stress (50) . However, secretion stress in Bacillus subtilis has been shown to induce the two-component response regulator CssRS, which results in the upregulation of proteins that aid in protein quality control at the cell surface, including the protease HtrA, the parvulin-type peptidylprolyl cis/trans isomerase PrsA, and SPase (51). The S. aureus genome does not encode a CssRS homolog, and instead the CWSS appears to control at least some of the same proteins via VraRS. This suggests that the upregulation of the CWSS plays a role analogous to that of the response mediated by the CssRS in B. subtilis. Nonetheless, while the CWSS may play a role in tolerating the secretion stress resulting from the inhibition of SPase, it does not contribute to high-level resistance.
Unlike the mechanism of arylomycin resistance previously characterized (15) , which is based on a mutation in SPase that reduces arylomycin binding, the mechanism characterized in this work is mediated by factors other than SPase. The mechanism appears to be linked to SAOUHSC_00331, which is annotated as a putative transcriptional regulator and which is homologous to the phage Cro repressor, suggesting that SAOUHSC_00331 is also a repressor. Susceptibility in the clinical isolates is correlated with the gene encoding Leu22, while resistance is correlated with the gene encoding Gln22, although it is unclear if resistance is actually mediated by this mutation or an allele to which it is genetically linked. However, the dominant mechanism of resistance ex vivo is mutation of SAOUHSC_00331. In one case, resistance was mediated by a loss-of-function mutation, which would cause derepression of the operon, and, in two cases, by an in-frame deletion, which also may cause derepression as they are within a predicted dimerization domain that may be required for function (40) . Thus, we speculate that resistance is mediated by derepression of genes under the control of SAOUHSC_00331. Based on genome context, SAOUHSC_00331 is likely to repress its own expression as well as that of three immediately downstream genes (SAOUHSC_00332 to SAOUHSC_00334) whose protein products are annotated as hypothetical membrane proteins. While this operon is strongly induced 30 min after arylomycin M131 treatment, its induction is somewhat attenuated by 120 min. Thus, partial derepression of these genes likely contributes to the immediate response to the antibiotic, while complete and heritable derepression appears to underlie high-level resistance. Presumably, it is the derepression of these and/or other genes regulated by SAOUHSC_00331 which renders resistance dependent on transcription and translation.
Clearly there are at least subtle differences between the resistance found among the clinical isolates and that evolved ex vivo. Synergy is observed between arylomycin A-C 16 and tunicamycin and the clinically derived resistant strains, while it is not observed with the strains evolved ex vivo. One possible origin of these differences may be different levels of derepression of the SAOUHSC_00331 operon. In the panel of clinical isolates, resistance was correlated with one of two SAOUHSC_00331 alleles, which suggests that it is mediated by either the difference between the two alleles (a single point mutation) or by another genetically linked difference. In either case, it is possible that SAOUHSC_00331 is only partially derepressed and that secretion thus requires additional factors in the presence of high-level SPase inhibition. In B. subtilis, divalent metal cations bound by the negative charges of teichoic acids appear to be required for the proper folding of extracytoplasmic proteins (25) . It is possible that with only partial SAOUHSC_00331 derepression, proper secretion with high-level SPase inhibition similarly depends on divalent metals provided by teichoic acids. Another possibility is that partial derepression, compared to full derepression, still results in the aberrant accumulation of membrane-anchored proteins and that this is synergistic with the cell wall stress caused by the absence of WTA. In addition, it is interesting to note that LtaS, which is required for the synthesis of lipoteichoic acid (the membranebound form of teichoic acid), is cleaved by SPase at a noncanonical internal site (52) (53) (54) and that over-and underexpression of LtaS results in resistance to arylomycin M131 (55) . In contrast, the ex vivo selections required resistance to high levels of the arylomycin, and each selected isolate possesses clear (stop codon) or likely (deletion in putative dimerization domain) loss-of-function mutations that would result in complete derepression of the genes regulated by SAOUHSC_00331. These arguments are also consistent with the synergy between arylomycin A-C 16 and tunicamycin in the clinical isolates. Synergy between arylomycin A-C 16 and tunicamycin was observed in strains that are resistant to arylomycin A-C 16 and sensitive to arylomycin M131 (a more potent SPase inhibitor) but not in strains that are resistant to both arylomycin A-C 16 and arylomycin M131. Presumably, synergy is lost as there is less reliance on additional factors due to the greater derepression of SAOUHSC_00331 required for resistance to the more potent SPase inhibitor.
Regardless of the mechanistic details, it is clear that the derepression of SAOUHSC_00331 allows cells to continue to grow despite the potent inhibition of SPase. Efforts to understand its molecular details are under way and will likely illuminate novel aspects of protein secretion and the response to secretion stress in S. aureus. Finally, further characterization of this mechanism, including an analysis of its effects on fitness and virulence in S. aureus and its conservation in other bacteria, will help further elucidate the potential of the arylomycins as broad-spectrum antibiotics.
